Cefdinir — Compare Prices at US & Canada Pharmacies

• Cefdinir is a third-generation cephalosporin antibiotic prescribed to treat bacterial infections including bronchitis, sinusitis, sore throat, and urinary tract infections.
• Frequently reported side effects include diarrhea, vomiting, headache, vaginal yeast infection, and rash; serious but uncommon reactions may include severe allergic responses, Stevens-Johnson syndrome, and C. difficile colitis.
• Cefdinir can affect laboratory test results, potentially raising blood glucose levels and liver enzyme values.
• Risk of side effects can be minimized by taking the medication exactly as prescribed, informing your healthcare provider of all existing conditions and current medications, and completing the entire prescribed course.

Cefdinir (brand name Omnicef) belongs to a class of antibiotics called third-generation cephalosporins. It is used to treat several types of bacterial infections, including bronchitis, sinusitis, pharyngitis (sore throat), and urinary tract infections. The medication works by eliminating harmful bacteria throughout the body. Available in capsule and oral suspension forms, cefdinir is typically prescribed for up to 10 days depending on the infection type.

Most patients tolerate cefdinir well, though side effects do occur. The most frequently encountered effects include diarrhea, vomiting, and headache. Serious adverse reactions exist but are uncommon and may include severe allergic reactions, Stevens-Johnson syndrome, and Clostridium difficile (C. difficile) infections. Because drug interactions are possible, inform your healthcare provider of any medical conditions or medications you take before starting cefdinir treatment.

Patients receiving cefdinir commonly experience the following side effects:

Diarrhea, yeast infection (candidiasis), nausea and vomiting, headache, abdominal pain, vaginal inflammation (vaginitis), rash, and indigestion or gas are among the most frequently reported effects.

Laboratory testing may also show clinically meaningful changes during treatment:

Elevated white blood cells in the urine, increased urinary protein (proteinuria), microscopic blood in the urine (microhematuria), elevated blood glucose, high eosinophil levels (eosinophilia—a specific type of white blood cell), and raised liver enzymes including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) may all be detected on lab work.

In an adult clinical trial, 15% of adults and adolescents experienced diarrhea.

Among pediatric patients, 8% experienced diarrhea and 0.8% reported abdominal pain. The highest rates were observed in children under 2 years of age, affecting 17% of that population.

If diarrhea becomes severe during treatment, contact your healthcare provider to rule out a C. difficile infection, which requires different management.

While cefdinir eliminates disease-causing bacteria, it can also destroy beneficial bacteria that normally inhabit the body. This disruption may lead to oral thrush or vaginal yeast infections during or after treatment.

A trial involving 5,093 adults and adolescents taking 600 mg daily found that 4% of women developed a vaginal yeast infection, while 0.2% experienced yeast infections at non-vaginal sites. In a separate pediatric study of 2,289 children, vaginal yeast infections occurred in 0.3% of girls treated with cefdinir, and fungal skin infections developed in 0.9% of all children in that group.

Although uncommon, serious adverse reactions can occur. These include severe allergic reactions (anaphylaxis), Stevens-Johnson syndrome (presenting as flu-like illness with painful rash and blistering), toxic epidermal necrolysis (rare condition involving skin peeling and blistering), exfoliative dermatitis (widespread skin redness and peeling), C. difficile infection with severe diarrhea and colitis, low neutrophil counts (neutropenia), low platelets (thrombocytopenia), hemolytic anemia, aplastic anemia, severe immune reactions (serum sickness), kidney damage, and liver toxicity.

Rash can accompany several cefdinir-related conditions, including allergic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis. Trial data show rash occurred in 0.9% of adults and adolescents taking cefdinir, while 3% of children experienced rash—predominantly those younger than 2 years.

Seek immediate emergency care if rash occurs alongside wheezing, chest or throat tightness, or difficulty breathing, as these signs may indicate a serious allergic reaction.

Cefdinir can eliminate protective bacteria in the gut microbiota, allowing C. difficile organisms to proliferate unchecked. These bacteria produce toxins that inflame the large intestine lining, a condition called pseudomembranous colitis. The resulting diarrhea ranges from mild to life-threatening, with symptoms including frequent watery or bloody diarrhea, abdominal pain and tenderness, cramping, nausea, fever, and loss of appetite.

Older patients often have multiple chronic conditions that could increase antibiotic-related side effect risk. Despite this theoretical concern, clinical trials showed cefdinir to be well-tolerated in older populations, with adverse reaction rates actually lower than those observed in younger adults.

Most cefdinir side effects resolve during treatment or shortly after stopping the medication, though some require additional care. Yeast infections, oral thrush, and C. difficile infections often need separate treatment with other medications.

Severe allergic reactions demand immediate medical attention. Warning signs include rash or hives, swollen or blistered skin areas, red peeling skin, wheezing, chest tightness, swelling of the mouth, face, lips, throat or tongue, and difficulty breathing.

Cefdinir may not suit everyone. Before beginning treatment, discuss your complete medical history with your healthcare provider, particularly if you have experienced kidney disease or dialysis, allergies to other antibiotics (especially cephalosporins or penicillins), colitis, diabetes, or seizure disorders.

Caution is warranted in patients with a creatinine clearance below 30 mL/min, as dosage reduction may be necessary. Cephalosporin antibiotics have been associated with seizures in patients with kidney impairment whose doses were not adjusted appropriately.

Patients with a history of colitis require careful monitoring, as C. difficile-associated diarrhea may be more severe in these individuals should it develop during treatment.

Cefdinir can increase blood sugar on its own. The liquid form of cefdinir also contains sugar, which may alter blood glucose levels. Diabetic patients should avoid using cefdinir suspension to ensure that blood sugar levels aren’t altered during treatment. Careful glucose monitoring is required when cefdinir must be used.

Cefdinir does not produce physical dependency or withdrawal reactions. However, as with all antibiotics, failure to complete the full course allows infections to persist or return.

Overdose is possible with cefdinir as with any medication. Overdose symptoms may include nausea, vomiting, stomach pain, diarrhea, and seizures. Seek emergency medical attention or contact Poison Control immediately if overdose is suspected.

The FDA has approved cefdinir for treating certain bacterial infections in children as young as 2 months old. It may be used to treat bacterial ear infections (otitis media), sinusitis, pharyngitis, tonsillitis, pneumonia, and skin infections caused by bacteria.

Cefdinir carries an FDA pregnancy category B classification. No human safety data exist, but animal studies revealed no known risks or adverse effects associated with cefdinir use during pregnancy. If you are pregnant, consult your healthcare provider about potential risks before taking this medication.

Cefdinir is considered compatible with breastfeeding. Human data regarding risk to the nursing infant are unavailable, but data from other cephalosporin antibiotics suggest no significant risk. The effect of cefdinir on breast milk supply remains unknown.

Cefdinir can interact with several medications and supplements. Inform your healthcare provider of all drugs, vitamins, and supplements you are taking before starting treatment.

Antacids containing magnesium or iron supplements may reduce cefdinir absorption and should be taken at least 2 hours before or after the antibiotic. Patients taking iron may notice reddish-colored stools, which results from a complex formed between cefdinir and iron in the digestive tract and is not related to bleeding.

Probenecid, used to treat gout by lowering uric acid, may increase cefdinir levels in the bloodstream. Hormonal birth control methods may be less effective during cefdinir therapy; backup contraception is recommended. Tetracycline antibiotics may alter how cefdinir functions in the body when taken concurrently.

Several measures can minimize the risk of unwanted cefdinir effects. Follow your healthcare provider's and pharmacist's directions precisely. If taking the liquid formulation, shake well before each use and measure doses with an appropriate syringe.

Cefdinir may be taken with or without food, though taking it with food can reduce stomach upset. Do not skip doses. If you miss a dose, take it as soon as you remember unless it is almost time for the next scheduled dose—in which case skip the missed dose. Never double up to compensate for a missed dose, as this increases the risk of side effects.

Avoid taking antacids or supplements containing magnesium or iron within 2 hours before or after your cefdinir dose, as these interfere with medication absorption. Disclose all medical conditions to your provider, as cefdinir may not be appropriate for certain health situations. If you have experienced allergic reactions to cephalosporin antibiotics, inform your provider before use.

Provide a complete medication list to your healthcare provider before treatment begins, including prescription drugs, over-the-counter products, supplements, and herbal remedies, as drug interactions are possible. Complete your entire prescribed course even if symptoms improve, since stopping early risks infection recurrence and antibiotic resistance.

Store cefdinir at room temperature, away from moisture, heat, and children's access. Discard any unused medication after your treatment ends.